Approval · Notice of Compliance 8173 · 2006
RITUXAN: Notice of Compliance 8173
Issued July 28, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8173
- Date
- July 28, 2006
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- The maintenance treatment of patients with follicular non-hodgkin's lymphoma who have responded to induction therapy with either chop or chop plus rituximab
- Therapeutic class
- Antineoplastic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RITUXAN | Not yet assigned | — |
Medicinal ingredients
- RITUXIMAB 10 MG per ML